Eduardo Mondlane University, Faculty of Medicine, CIMed, Maputo, Mozambique.
Expert Opin Pharmacother. 2010 Jun;11(8):1277-93. doi: 10.1517/14656561003733599.
Malaria infection during pregnancy is a major public health problem worldwide, with 50 million pregnancies exposed to the infection every year. Approximately 25,000 maternal deaths and between 75,000 and 200,000 infant deaths could be prevented each year by effective malaria control in pregnancy. Antimalarial drug treatment and prevention has been hampered by the appearance of drug resistance, which has been a particular problem in pregnancy due to the inherent safety issues.
New antimalarial drugs and combinations are being studied but there is not yet sufficient information on their efficacy or, more importantly, on their safety in pregnancy. This article provides an overview of the relevance of the topic and reviews the current antimalarial drugs recommended for pregnancy, as well as the guidelines for both treatment and prevention in women living in endemic areas and for travellers.
Updated information on the drugs currently used for malaria treatment and prevention in pregnancy, including new drugs under development, is provided. The gaps on efficacy and safety information for use during pregnancy are also discussed.
Prevention and case management of malaria during pregnancy is based on risk-benefit criteria and poses one of the greatest challenges to current malaria control.
怀孕期间疟疾感染是全球范围内的一个主要公共卫生问题，每年约有 5000 万例妊娠受到感染。如果在怀孕期间有效控制疟疾，每年可预防约 2.5 万例孕产妇死亡和 7.5 万至 20 万例婴儿死亡。抗疟药物治疗和预防因药物耐药性的出现而受到阻碍，由于内在的安全问题，这种情况在怀孕期间尤为突出。
正在研究新的抗疟药物和组合，但关于其疗效，更重要的是其在怀孕期间的安全性，目前还没有足够的信息。本文概述了该主题的相关性，并回顾了目前推荐用于妊娠的抗疟药物，以及在疟疾流行地区的妇女和旅行者中进行治疗和预防的指南。
提供了关于目前用于妊娠疟疾治疗和预防的药物的最新信息，包括正在开发的新药。还讨论了在怀孕期间使用的疗效和安全性信息方面的差距。
根据风险效益标准，预防和治疗妊娠期间疟疾是疟疾控制面临的最大挑战之一。
